Arbutus生物制药

Moderna

Arbutus Biopharma and Genevant Sciences Sue Moderna Over Covid-19 Vaccine Patents

Arbutus Biopharma

Moderna faces $5 billion mRNA patent lawsuit after "Star Trek" ruling: Court denies Moderna's request for summary judgment, citing patent infringement over COVID-19 vaccine technology.

Moderna shares fall 5.17% intraday after analyst downgrades and pipeline cuts spark profit concerns.

Sandisk

Micron Technology

Western Digital

Seagate Technology

S&P 500 Sector Performance and Analyst Forecasts for 2026

AVITA Medical

Yuanbao

Medallion Financial

Lincoln National

26 Analysts' Rare Stock Picks for January 2026

Catalyst<ul> <li>Strong cash reserves relative to market value suggest financial stability for MRNA.</li></ul>Risk<ul> <li>Technical indicators show a weak overall trend with bearish signals dominating in recent periods.</li> <li>Market expectations for MRNA tend to be pessimistic according to analyst ratings.</li> <li>Fund flow analysis indicates a negative overall trend, with mixed inflow ratios across different investor sizes.</li></ul>

Key Factors

A federal judge denied Moderna’s request for summary judgment in a $5 billion patent infringement lawsuit over its COVID-19 vaccine technology, forcing a trial to determine patent validity and infringement.Moderna faces a patent lawsuit from Arbutus Biopharma and Genevant Sciences, who claim Moderna violated patent law by using their lipid nanoparticle technology during Operation Warp Speed.Moderna’s stock dropped 5.17% intraday after analyst downgrades, pipeline cuts, and a $1.5 billion loan to extend liquidity, signaling concerns over long-term growth and profitability.

Recent Updates

MRNA News